Project Abstract

Abstract
Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. The pathophysiology of IBS is complex and multifactorial, involving disturbances in gut microbiota composition and low-grade inflammation. Probiotics have emerged as a potential therapeutic option for managing IBS symptoms by modulating the gut microbiota and immune response. This research aimed to investigate the effect of probiotics supplementation on gut microbiota composition and inflammation in patients with IBS. The study utilized a randomized controlled trial design involving 100 patients diagnosed with IBS. Participants were randomly assigned to either the probiotics supplementation group or the placebo group for a duration of 12 weeks. Stool samples were collected at baseline, 6 weeks, and 12 weeks to analyze changes in gut microbiota composition using next-generation sequencing techniques. In addition, serum inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) were measured to assess the impact of probiotics on systemic inflammation. The findings revealed that probiotics supplementation led to significant changes in the gut microbiota composition of IBS patients. Specifically, there was an increase in beneficial bacteria such as Lactobacillus and Bifidobacterium, along with a reduction in pathogenic species. Moreover, probiotics supplementation was associated with a decrease in serum CRP and IL-6 levels, indicating a reduction in systemic inflammation. The results of this study provide valuable insights into the therapeutic potential of probiotics in the management of IBS. By modulating the gut microbiota and attenuating inflammation, probiotics supplementation offers a promising approach for alleviating symptoms and improving the quality of life in patients with IBS. Further research is warranted to elucidate the underlying mechanisms of probiotics action and optimize treatment strategies for individuals with IBS. In conclusion, the findings of this research highlight the beneficial effects of probiotics supplementation on gut microbiota composition and inflammation in patients with Irritable Bowel Syndrome. These results contribute to the growing body of evidence supporting the use of probiotics as a safe and effective adjunct therapy for managing IBS symptoms.

Project Overview

The project topic "Effect of Probiotics Supplementation on Gut Microbiota and Inflammation in Patients with Irritable Bowel Syndrome" aims to investigate the potential benefits of probiotics in managing gut microbiota and inflammation in individuals diagnosed with Irritable Bowel Syndrome (IBS). Irritable Bowel Syndrome is a common gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. It is believed to be linked to disturbances in the gut microbiota and low-grade inflammation in the intestines. Probiotics are live microorganisms that, when consumed in adequate amounts, confer health benefits to the host. These beneficial bacteria are known to modulate the composition of the gut microbiota and have anti-inflammatory properties. By supplementing IBS patients with probiotics, this research seeks to explore how these interventions may positively impact gut health and alleviate symptoms associated with IBS. The study will delve into existing literature on probiotics, gut microbiota, inflammation, and Irritable Bowel Syndrome to establish a theoretical framework for the research. Through a comprehensive literature review, the project aims to synthesize current knowledge and identify gaps in understanding the mechanisms by which probiotics influence gut microbiota and inflammation in individuals with IBS. The research methodology will involve designing a randomized controlled trial to assess the effects of probiotics supplementation in IBS patients. Participants will be divided into intervention and control groups, with the intervention group receiving probiotic supplements while the control group receives a placebo. Various outcome measures, including changes in gut microbiota composition, levels of inflammatory markers, and symptom severity, will be evaluated before and after the intervention period. The findings of this study are expected to provide valuable insights into the potential of probiotics as a therapeutic approach for managing gut dysbiosis and inflammation in individuals with Irritable Bowel Syndrome. By elucidating the mechanisms underlying the effects of probiotics on gut health, this research aims to contribute to the development of targeted interventions for improving the quality of life of IBS patients. In conclusion, the project on the "Effect of Probiotics Supplementation on Gut Microbiota and Inflammation in Patients with Irritable Bowel Syndrome" holds promise for advancing our understanding of the role of probiotics in gut health and inflammatory conditions. Through rigorous scientific inquiry and robust methodology, this research endeavors to shed light on novel therapeutic strategies for managing Irritable Bowel Syndrome and enhancing patient outcomes.